Immunotherapy plus chemotherapy before and after surgery for MSI-high colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving an immunotherapy drug (tislelizumab) together with chemotherapy before and after surgery can improve outcomes for people with a specific type of colorectal cancer (MSI-high). The goal is to see if this treatment helps shrink the tumor and reduces the risk of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colon or rectal cancer confirmed by biopsy.
- Your tumor must test positive for a genetic marker called MSI-high (or dMMR) — this makes the cancer more likely to respond to immunotherapy.
- Your cancer must be stage II or III, meaning it has not spread to distant organs but may have reached nearby lymph nodes.
- You should be in good overall health (able to carry out daily activities) and be expected to live at least 12 weeks.
- You cannot have had any prior cancer treatment (like chemotherapy or radiation) for this cancer.
- You should not have an active autoimmune disease or be taking drugs that severely suppress your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
Hear when a new Tislelizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.